Cargando…

Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer

Vascular endothelial growth factor (VEGF) receptors consist of three cell-membrane type receptors (VEGFR-1, VEGFR-2 and VEGFR-3), and soluble form of VEGFR-1 (sVEGFR-1), an intrinsic negative counterpart of the VEGF. In this study, we measured intratumoral protein levels of free and total VEGF, VEGF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bando, H, Weich, H A, Brokelmann, M, Horiguchi, S, Funata, N, Ogawa, T, Toi, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362070/ https://www.ncbi.nlm.nih.gov/pubmed/15668703 http://dx.doi.org/10.1038/sj.bjc.6602374

Ejemplares similares

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
por: Jürgensmeier, J M, et al.
Publicado: (2013)

The balance of VEGF-C and VEGFR-3 mRNA is a predictor of lymph node metastasis in non-small cell lung cancer
por: Takizawa, H, et al.
Publicado: (2006)

VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
por: Scartozzi, M, et al.
Publicado: (2013)

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
por: Fuchs, Charles S, et al.
Publicado: (2016)

Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells
por: Garvin, S, et al.
Publicado: (2005)

Profiling of VEGFs and VEGFRs as Prognostic Factors in Soft Tissue Sarcoma: VEGFR-3 Is an Independent Predictor of Poor Prognosis
por: Kilvaer, Thomas K., et al.
Publicado: (2010)

Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors
por: Farace, F, et al.
Publicado: (2011)

Editing VEGFR2 Blocks VEGF-Induced Activation of Akt and Tube Formation
por: Huang, Xionggao, et al.
Publicado: (2017)

VEGF-VEGFR Signals in Health and Disease
por: Shibuya, Masabumi
Publicado: (2014)

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma
por: Nascimento, Catarina, et al.
Publicado: (2021)

Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression
por: Wang, Min, et al.
Publicado: (2019)

Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer
por: Dziobek, Konrad, et al.
Publicado: (2019)

VEGF-dependent tumor angiogenesis requires the inverse and reciprocal regulation of VEGFR1 and VEGFR2
por: Zhang, Zhaocheng, et al.
Publicado: (2009)

Genetic variations in VEGF and VEGFR2 and glioblastoma outcome
por: Sjöström, S., et al.
Publicado: (2010)

Targeting VEGF/VEGFR to Modulate Antitumor Immunity
por: Yang, Ju, et al.
Publicado: (2018)

Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma
por: Pritchard-Jones, R O, et al.
Publicado: (2007)

The role of the VEGF-C/VEGFR-3 axis in cancer progression
por: Su, J-L, et al.
Publicado: (2007)

Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
por: Jie, H-B, et al.
Publicado: (2013)

VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo
por: Rennel, E S, et al.
Publicado: (2009)

Counterbalance: modulation of VEGF/VEGFR activities by TNFSF15
por: Yang, Gui-Li, et al.
Publicado: (2018)

The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy
por: Mabeta, Peace, et al.
Publicado: (2022)

Structure-Based Design of Peptides Targeting VEGF/VEGFRs
por: Di Stasi, Rossella, et al.
Publicado: (2023)

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
por: Dev, I K, et al.
Publicado: (2004)

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer
por: Kut, C, et al.
Publicado: (2007)

Seasonal expressions of VEGF and its receptors VEGFR1 and VEGFR2 in the prostate of the wild ground squirrels (Spermophilus dauricus)
por: Yao, Yuchen, et al.
Publicado: (2021)

Regulation of Pathologic Retinal Angiogenesis in Mice and Inhibition of VEGF-VEGFR2 Binding by Soluble Heparan Sulfate
por: Nishiguchi, Koji M., et al.
Publicado: (2010)

VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding
por: Lanitis, Evripidis, et al.
Publicado: (2021)

Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer
por: Hiraoka, N, et al.
Publicado: (2015)

The Role of the VEGF-C/VEGFRs Axis in Tumor Progression and Therapy
por: Chen, Jui-Chieh, et al.
Publicado: (2012)

Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
por: Li, Yu-Ling, et al.
Publicado: (2016)

VEGF-A splice variants bind VEGFRs with differential affinities
por: Mamer, Spencer B., et al.
Publicado: (2020)

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
por: Liu, Guihong, et al.
Publicado: (2021)

Pericytes regulate VEGF-induced endothelial sprouting through VEGFR1
por: Eilken, Hanna M., et al.
Publicado: (2017)

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008)

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
por: Gavalas, N G, et al.
Publicado: (2012)

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
por: Rochefort, Pauline, et al.
Publicado: (2017)

Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway
por: Joshi, H, et al.
Publicado: (2012)

Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.
por: Robak, Ewa, et al.
Publicado: (2003)

Expressions of VEGF-A and VEGFR-2 in placentae from GDM pregnancies
por: Meng, Qian, et al.
Publicado: (2016)

Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2
por: Peach, Chloe J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_e86b5phkgg1bfeoo6f9if8bssu